herpes simplex keratitis
Ophthalmology · 2015–2021
3decisions
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| aciclovir Treatment of Herpes simplex keratitis (HSK) | Mar 2021 | Not recommended | input received |
| aciclovir Herpes simplex keratitis — an alternative ophthalmic treatment to manage corneal infection caused by herpes simplex virus. | Jul 2015 | Recommended with restriction | no section in document |
| aciclovir Treatment of herpes simplex keratitis (eye infection). | Jul 2015 | Recommended with restriction | no section in document |
What the PBS pays
$1M in government benefit over 2024–25, across 30,145 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| aciclovir | $0.6M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.